Sign In
Last checked at 
10 Sep 2012 15:19
Preliminary Results Date
10 September 2012
Epistem Holdings Plc (LSE: EHP), the biotechnology and personalised medicine company will be announcing its preliminary results for the six months ended 30 June 2012 on Tuesday, 16 October 2012.
An analysts' meeting will be held at the offices of Peel Hunt LLP, Moor House, 120 London Wall, London EC2Y 5ET at 9.30 am.
Epistem Plc | ||
Matthew Walls | Chief Executive Officer | +44 (0) 7887 501998 |
John Rylands | Finance Director | +44 (0) 161 606 7244 |
Peel Hunt LLP | ||
James Steel | +44 (0) 207 418 8900 | |
Vijay Barathan | +44 (0) 207 418 8900 | |
De Facto Financial | ||
Mike Wort / Anna Dunphy | +44 (0) 20 7556 1064 |
Notes to Editors:
About Epistem
Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and pharmacogenomics in the areas of oncology, gastrointestinal, dermatological and infectious disease.
Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.
Follow the stocks
